期刊文献+

手性药物的毒理学特点及安全性评价要点 被引量:6

Toxicological characteristics of chiral drugs and their toxicology evaluation
下载PDF
导出
摘要 目前临床上使用的很多药物属于手性药物的消旋体,但手性药物的不同对映体与生物大分子的作用具有不同的选择性,其立体选择性能够对机体产生不同的毒性作用,因此手性药物的安全性评价日益受到重视,各国政府纷纷颁布法规规范手性药物的毒理学评价。通过比较分析不同手性异构体的毒理学作用特点,能够加快研发过程,为临床提供更安全的药物。现综述手性药物独特的毒性作用特点以及不同国家手性药物的安全性评价要点,阐述其毒理学评价基本过程,为手性药物的毒理学评价提供参考。 There are many chiral drugs in clinical application. The different enantiomeres of a chiral drug can have distinct effects on the biomacromolecules. The stereoselectivity of chiral drug results in different toxic reactions, which can have important impacts on human health. Therefore, the toxicology evaluation of chiral drugs should be paid more and more attention, and many countries published the regulations to standard the toxicology evaluation. Through the comparison and analysis of the toxicological reactions, the developing process can be speed up, and the safer drugs can be provided. This paper outlined the distinctive toxic characteristics and different statements in development of chiral drugs, elucidated the process of the toxicology evaluation, and offered information for the toxicology evaluation of chiral drugs.
出处 《中国新药杂志》 CAS CSCD 北大核心 2008年第16期1372-1374,共3页 Chinese Journal of New Drugs
基金 国家自然科学基金重大课题资助项目(203900508)
关键词 手性药物 立体选择性 安全性评价 chiral drug stereoselectivity safety evaluation
  • 相关文献

参考文献7

  • 1MIZUTA Y, IMAIZUMI T. Alpha beta-blockers for patients with hypertension [ J ]. Nippon Rinsho ,2006,64 ( S6 ) : 305 - 309.
  • 2BARDSLEY H,GRISTWOOD R,BAKER H,et al. A comparison of the cardiovascular effects of levobupivacaine and rac-bupivacaine following intravenous administration to healthy volunteers [ J ]. Br J Clin Pharmacol, 1998,46 ( 3 ) :245 - 249.
  • 3PATIL PA, KOTHEKAR MA. Development of safer molecules through chirality[ J]. Indian J Med Sci,2006,60(10) :427 -437.
  • 4李更,王丽韫,郑建全,刘河,仲伯华,刘克良.盐酸苯环壬酯左旋体及光学异构体抗动物晕动病药效学研究[J].中华航空航天医学杂志,2006,17(2):87-91. 被引量:6
  • 5FDA. FDA'S POLICY STATEMENT FOR THE DEVELOPMENT OF NEW STEREOISOMERIC DRUGS. 1992[EB/OL].[2005 - 07 - 06 ]. http ://www. fda. gov/cder/guidance/stereo.html.
  • 6Health Canada. Stereochemical issues in chiral drug development [ EB/OL]. [ 2000 -02 - 14 ]. http://www, hc-sc.gc. ca/dhpmps/prodpharma/applic-demande/guide-ld/chem/stereo_e.html.
  • 7国家食品药品监督管理局.药品注册管理办法[EB/OL].[2007-07-10].http://www.sda.gov.cn/WS01/CL0053/24529.html.

二级参考文献8

共引文献12

同被引文献47

引证文献6

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部